The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.

Saved in:
Bibliographic Details
Title: The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
Authors: Hunter NB; Fred Hutchinson Cancer Center, University of Washington, Seattle, WA., Parsons HA; Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.; Dana Farber Cancer Institute, Boston, MA., Cope L; Johns Hopkins University, Baltimore, MD., Canzoniero JV; Johns Hopkins University, Baltimore, MD., Navarro FCP; Personalis, Fremont, CA., El-Refai S; Personalis, Fremont, CA., Anampa JD; Montefiore Einstein Comprehensive Cancer Center, Bronx, NY., Sparano JA; Montefiore Einstein Comprehensive Cancer Center, Bronx, NY., Rimawi M; Baylor College of Medicine, Houston, TX., Storniolo AM; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Mainor C; Medstar Georgetown University-Hospital-Lombardi Comprehensive Cancer Center, Washington, DC., Nanda R; University of Chicago, Chicago, IL., DeMichele A; University of Pennsylvania, Philadelphia, PA., Gupta GP; University of North Carolina, Chapel Hill, NC., Stringer-Reasor EJ; University of Alabama at Birmingham, Birmingham, AL., Lynce F; Dana Farber Cancer Institute, Boston, MA.; Medstar Georgetown University-Hospital-Lombardi Comprehensive Cancer Center, Washington, DC., Cobain EF; Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Puhalla S; University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA., Jankowitz R; University of Pennsylvania, Philadelphia, PA.; University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA., Rexer B; Vanderbilt University Medical Center, Nashville, TN., Mayer I; Vanderbilt University Medical Center, Nashville, TN., Hwang ES; Duke University and Duke Cancer Institute, Durham, NC., Blackwell K; Duke University and Duke Cancer Institute, Durham, NC., El Ayass W; Tidal Health, Peninsula Regional Medical Center, Salisbury, MD., Lee Y; Anne Arundel Medical Center, Annapolis, MD., Tweed C; Anne Arundel Medical Center, Annapolis, MD., Wilkinson M; Johns Hopkins University, Baltimore, MD.; Inova Schar Cancer, Fairfax, VA., Pennisi A; Inova Schar Cancer, Fairfax, VA., Sun B; Johns Hopkins University, Baltimore, MD., Wright P; Johns Hopkins University, Baltimore, MD., Gralow JR; Fred Hutchinson Cancer Center, University of Washington, Seattle, WA., Chen R; Personalis, Fremont, CA., Boyle SM; Personalis, Fremont, CA., Stearns V; Johns Hopkins University, Baltimore, MD., Wolff AC; Johns Hopkins University, Baltimore, MD., Park BH; Vanderbilt University Medical Center, Nashville, TN.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 May 10; Vol. 44 (14), pp. 1283-1295. Date of Electronic Publication: 2026 Mar 10.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO-25-02934